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Sydenham’s chorea is often regarded as a relatively benign and self-limiting condition. Treatment is typically
symptomatic, although occasionally immunomodulatory therapies are required in severe forms. Here we report a
girl who was affected with the severe variant, chorea paralytica, who responded dramatically and rapidly to
plasmapheresis, having failed other therapies.
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Sydenham’s chorea (SC) is the neurological manifest-
ation of rheumatic fever, a complication of group A
beta-hemolytic streptococcal infection. Although the in-
cidence of SC has declined markedly, particularly in de-
veloped countries, it remains the most prevalent cause
of acute chorea in children worldwide [1]. SC accounts
for almost all cases of acquired chorea in childhood in
the United States [2].
SC is considered to be a humorally-mediated auto-
immune disorder and, in addition to chorea, is charac-
terized by decreased muscle tone, motor impersistence,
and psychiatric and behavioral symptoms, particularly
obsessive-compulsive symptoms and hyperactivity [1,3].
The usual age at onset of SC is around 9 years old with
a female predominance [1].
This condition is usually managed with anti-choreic
drugs, such as valproic acid and neuroleptics, in addition
to benzathine penicillin prophylaxis to prevent recur-
rence of streptococcal infection [1].
Despite treatment with valproic acid and neuroleptics,
5% of patients with SC fail to respond [1,4]. We report a
patient with a severe form of SC, the so-called chorea
paralytica or chorea mollis [1], who responded dramatic-
ally and rapidly to plasmapheresis after failure of con-
ventional therapy and intravenous corticosteroids.* Correspondence: ruth.walker@mssm.edu
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Two weeks following a throat infection, a previously
healthy 16-year-old girl acutely developed generalized
involuntary movements. Within a few days, she became
bedridden, incapable of standing or walking without as-
sistance, and requiring a naso-gastric tube for feeding.
On initial examination, the most relevant clinical find-
ings were lack of spontaneous speech, generalized cho-
rea, and a severe decrease in muscle tone, to the extent
that she was unable even to sit on the bed (Additional
file 1), corresponding to chorea paralytica. Strength and
deep tendon reflexes were normal. No other abnormal
signs were observed. Antistreptolysin O (ASO) titer was
elevated (300 U, normal value <200), as was anti-DNase
B titer (300 units/mL, normal <170 units/mL). There
were no abnormalities of serum glucose, antinuclear
antibodies, antiphospholipid antibodies, thyroid function
tests or syphilis serology. Cerebrospinal fluid and brain
MRI were normal. Echocardiogram revealed no signs of
carditis. Anti-basal ganglia antibody testing was not
available. There was no family history of neurologic dis-
ease or use of any drug which might induce a movement
disorder.
The diagnosis of SC was made, and she was treated with
valproic acid (maximum dose 1.5 g/day) and risperidone
(maximum dose 3 mg/day) without a reduction in chorea.
Methylprednisolone 1 g i.v daily for 3 days followed by
prednisone 1 mg/kg p.o. produced no change in her
neurologic status. Five rounds of plasmapheresis were per-
formed with a rapid improvement in hypotonia, starting
3 days after the last treatment (Additional file 1). Markedl. This is an Open Access article distributed under the terms of the Creative
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file 1). She remains on benzathine penicillin prophylaxis
since hospital discharge.
Conclusions
SC is often considered a benign, self-limiting condition
that usually spontaneously remits after 6–7 months. How-
ever, in contradiction to this perception, Cardoso et al.
found that after 2 years 50% of SC subjects continue to
have disabling persistent chorea, despite ongoing treat-
ment [4]. SC can be very disabling even at presentation, as
in our case.
There are very few reports regarding the use of plasma-
pheresis in SC. In an unblinded study of 18 patients
treated with plasmapheresis, Garvey et al. reported that 8
cases had a marked response [5].
Our report supports the early use of plasmapheresis in
severe cases of SC (chorea paralytica) which may be less
responsive to conventional symptomatic and immuno-
modulatory therapy, such as corticosteroids. Although
their biological role has not been unequivocally demon-
strated, anti-basal ganglia antibodies (ABGA) have been
found in 100% of patients with acute SC [6]. Although
plasmapheresis is regarded as an experimental therapy
in SC [1,7], the presence of these ABGA provides a ra-
tionale for its use [5,8,9]. Historical reports demonstrate
that severely affected children improve more slowly
than those with milder symptoms. In the Garvey study
of 18 moderate and severe cases [5], as in the present
case, there was a rapid and dramatic response, [5],
occurring during one month of therapy, or in a few days
as seen here.
In cases of chorea paralytica it is unreasonable to wait
months for a response after conventional therapy, and a
more aggressive approach is justified. However, at the
present time, according to evidence-based guidelines,
there is insufficient evidence to support or refute the use
of plasmapheresis in Sydenham chorea (Class III evi-
dence, Level U) [7].
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Additional file 1: Segment 1 shows the patient before treatment
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ABGA: Anti-basal ganglia antibodies; ASO: Antistreptolysin O; SC: Sydenham’s
chorea.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MM diagnosed and treated the patient and prepared the first draft of the
manuscript; RHW revised the manuscript for intellectual content; DS assisted
with diagnosis and treatment; VR assisted with diagnosis and treatment; All
authors read and approved the final manuscript.
Author details
1Department of Neurology, Clinica Las Condes, Santiago, Chile. 2Department
of Neurology (127), James J. Peters Veterans Affairs Medical Center, 130 W.
Kingsbridge Road, Bronx, NY 10468, USA. 3Mount Sinai School of Medicine,
New York, USA. 4Department of Neurology, Hospital Barros Luco, Santiago,
Chile.
Received: 14 August 2014 Accepted: 29 October 2014
References
1. Cardoso F: Sydenham's chorea. Curr Treat Options Neurol 2008, 10:230–235.
2. Zomorrodi A, Wald ER: Sydenham's chorea in western Pennsylvania.
Pediatrisc 2006, 117:e675–e679.
3. Swedo SE, Leonard HL, Schapiro MB, Casey BJ, Mannheim GB, Lenane MC,
Rettew DC: Sydenham's chorea - physical and psychological symptoms
of St.Vitus dance. Pediatrics 1993, 91:706–713.
4. Cardoso F, Vargas AP, Oliveira LD, Guerra AA, Amaral SV: Persistent
Sydenham's chorea. Movement Disord 1999, 14:805–807.
5. Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE: Treatment of
Sydenham's chorea with intravenous immunoglobulin, plasma
exchange, or prednisone. J Child Neurol 2005, 20:424–429.
6. Church AJ, Cardoso F, Dale RC, Lees AJ, Thompson EJ, Giovannoni G: Anti-basal
ganglia antibodies in acute and persistent Sydenham's chorea. Neurology
2002, 59:227–231.
7. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A: Evidence-
based guideline update: plasmapheresis in neurologic disorders: report of
the therapeutics and technology assessment subcommittee of the
American academy of neurology. Neurology 2011, 76:294–300.
8. Walker K, Brink A, Lawrenson J, Mathiassen W, Wilmshurst JM: Treatment of
Sydenham chorea with intravenous immunoglobulin. J Child Neurol 2012,
27:147–155.
9. Fusco C, Ucchino V, Frattini D, Pisani F, Della GE: Acute and chronic
corticosteroid treatment of ten patients with paralytic form of
Sydenham's chorea. Eur J Paediatr Neurol 2012, 16:373–378.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
